Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up
Among individuals aged 60 years or older, mRNA XBB-vaccination provided meaningful, albeit limited to first four months post-vaccination, protection against COVID-19 hospitalization due to XBB, JN and KP subvariants. Better vaccines are needed to effectively protect older adults against COVID-19 hospitalizations.
Authors
- Rodica Gilca (ORCID: https://orcid.org/0000-0002-8558-3967)
- Sara Carazo (ORCID: https://orcid.org/0000-0003-0711-6703)
- Denis Talbot (ORCID: https://orcid.org/0000-0003-0431-3314)
- Gaston De Serres (ORCID: https://orcid.org/0000-0002-1592-5167)
- Philippe De Wals (ORCID: https://orcid.org/0000-0002-9239-3096)
- Danuta M. Skowronski (ORCID: https://orcid.org/0000-0001-5870-6733)
- Judith Fafard (ORCID: https://orcid.org/0000-0003-4355-1294)
- Étienne Racine (ORCID: https://orcid.org/0000-0003-4266-0421)
- Charles-Antoine Guay (ORCID: https://orcid.org/0009-0002-9774-9095)
- Iulia Gabriela Ionescu
- Nicholas Brousseau (ORCID: https://orcid.org/0000-0001-6042-3177)
- Chantal Sauvageau (ORCID: https://orcid.org/0000-0002-4300-1658)
- Jonathan Phimmasone
Institutions
- Université de Sherbrooke (CA)
- BC Centre for Disease Control (CA)
- Institut National de Santé Publique du Québec (CA)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Centre hospitalier de l'Université Laval (CA)
- Université Laval (CA)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1371/journal.pone.0325269
- Citations
- 7
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 9.77
Funders
- Ministère de la Santé et des Services sociaux